Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial
Allergy2020Vol. 76(6), pp. 1789–1799
Citations Over TimeTop 10% of 2020 papers
Isao Ohsawa, Daisuke Honda, Yusuke Suzuki, Tomoo Fukuda, Keisuke Kohga, Eishin Morita, Shinichi Moriwaki, Osamu Ishikawa, Yoshihiro Sasaki, Masaki Tago, Greg Chittick, Melanie Cornpropst, Sharon C. Murray, Sylvia Dobo, Enikő Nagy, Sharon Van Dyke, Lacy Reese, Jessica Best, Heather A. Iocca, Phil Collis, William Sheridan, Michihiro Hide
Abstract
Orally administered, once-daily berotralstat 150 mg significantly reduced the frequency of HAE attacks and was safe and well tolerated, supporting its use as a prophylactic therapy in patients with type 1 or 2 HAE in Japan.
Related Papers
- → Brazilian Guidelines for Hereditary Angioedema Management - 2017 Update Part 1: Definition, Classification and Diagnosis(2018)28 cited
- → Angioedema without wheals: a clinical update(2021)18 cited
- → Preliminary results of a non-interventional single-center study evaluating the efficacy of long-term use of lanadelumab in routine clinical practice in the Russian Federation(2023)2 cited
- → Hereditary Angioedema as a Cause of Transient Abdominal Pain(2002)15 cited
- → Complement Component Analysis in Angioedema(1975)11 cited